Skip to main content
Equibles
OTLK logo

OTLK · Outlook Therapeutics, Inc. · Metrics

Track OTLK — free

Use OTLK with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OTLK.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.56 +0.04 (+7.94%) At close · Oct 21
Rebalance outlook locked
Going-concern doubt — flagged Aug 18, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Because our cash and cash equivalents, together with $51.1 million of net proceeds from our August 2026 Offering, will not be adequate to fund our currently planned operations through at least the 12 months from the date of this Quarterly Report, there is substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Aug 18, 2026
Market Cap
$126.59M
Shares
243.45M
Volume · Oct 21 3M Avg daily vol (3M) 12.61M

OTLK metrics

62 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.56
Market cap
$126.59M

Price action

20 metrics
Price change (1W)
-7.8%
Price change (30D)
-24.2%
Price change (3M)
-63.4%
Price change (6M)
+63.0%
Price change (YTD)
-67.1%
Price change (1Y)
-64.9%
Trailing year
Price change (5Y)
—
52-week high
$2.47
52-week low
$0.20
Change from 52-week high
-78.9%
Change from 52-week low
+162.6%
Annualized volatility
152.1%
Annualized volatility (3M)
106.0%
Beta
1.1
RSI (14D)
38.8
Price vs SMA 50
-19.8%
Price vs SMA 200
-21.7%
Avg volume (3M)
12.63M
Relative volume
0.3
Average dollar volume
$10.50M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
243.45M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-50.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-14

Profitability

9 metrics
Gross margin
4.0%
Operating margin
-4,744.3%
Trailing 12 months
Net margin
-4,416.2%
Gross profit (TTM)
−$2.28M
Operating profit (TTM)
−$55.64M
Net income (TTM)
−$61.12M
Trailing 12 months
Diluted EPS (TTM)
$-1.04
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.60

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+270.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-233.4%
Debt / equity
—
Current ratio
0.8
EBITDA (TTM)
−$55.53M
Free cash flow (TTM)
—
Quick ratio
0.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$11.24M
Total assets
$26.18M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$56.15M
Capital expenditures (TTM)
$437,307
R&D (TTM)
$17.36M
SG&A (TTM)
$36.00M
Stock compensation (TTM)
$4.25M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
69
13F filer change QoQ
+12
Institutional ownership
8.9%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
7.5%
Private-fund adviser ownership
4.3%
Active holders' share change QoQ
+58.2%
Holder tenure
4.9
Price vs estimated holder cost
+133.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
2.0%

Short interest

3 metrics
Short interest
13.1%
Latest settlement · 7.1 days to cover
Days to cover
7.1d
Short-squeeze score
64 / 100

Insider activity

2 metrics
Net insider buying (90D)
$2.60M
Insider-sentiment score
97 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1649989 CUSIP 69012T305 13F (30d) 19 filings 8 filers Visit website Investor relations